SALEM, NH--(Marketwired - Mar 14, 2017) - ProPhotonix Limited (OTC: STKR) (AIM: PPIX)
OTC: STKR; AIM: PPIX
PROPHOTONIX ANNOUNCES PRELIMINARY RESULTS FOR THE YEAR ENDED DECEMBER 31, 2016
Annual General Meeting Date
(Salem, New Hampshire, March 14, 2017) ProPhotonix Limited (OTC: STKR and London Stock Exchange - AIM: PPIX), a high technology designer and manufacturer of LED illumination systems and laser diode modules, with operations in Ireland and the United Kingdom, today announces its unaudited preliminary results for the year ended December
Annual General Meeting and Posting of Results
The Company will hold the Annual General Meeting of the Shareholders on May 18, 2017 at 2:00 PM British Summer Time at the offices of K&L Gates LLP, One New Change, London EC4M 9AF. Only shareholders who hold shares at the close of business on the record date of March 23, 2017 may vote at the Annual General Meeting. The Company intends to publish the audited accounts for 2016 and post them to the Company's web site on or about April 6, 2017.
- Revenue increased 13% to $16.2 million (2015: $14.4 million)
- Net Income increased 348% to $1.3 million (2015: $0.3 million)
- EBITDA increased 49% to $1.8 million (2015: $1.2 million)
- Operating profit increased 89% to $1.5 million (2015: $0.8 million)
- Gross profit margin improved to 45.4% (2015: 41.4%)
- Gross profit increased 24% to $7.4 million (2015: $6.0 million)
- Order bookings of $16.7 million (2015: $15.7 million)
- 1.03 Book-to-Bill ratio (2015: 1.09)
- Percentage revenue by market sectors: industrial 82%, medical 14%, and homeland security & defense 4% (2015: industrial 79%, medical 17%, and homeland security and defense 4%)
- Percentage revenue by geography: 48% Europe,42% North America and 10% Rest of World (2015: 47% Europe, 41% North America and 12% Rest of World)
- Term debt declined $1.1 million to $0.4 million at December 31, 2016
- Available borrowing capacity of $0.4 million from its revolving credit facility at December 31, 2016 (2015: $0.5 million)
Tim Losik, President & CEO, Commented:
"We continued our positive financial momentum from the prior year and have now achieved seven consecutive half-yearly periods of positive EBITDA, five consecutive half-yearly periods of positive operating income, and a second year of net income. As compared to 2015, sales grew 13% to $16.2 million, operating income increased 89%, EBITDA increased 49%, and net income increased 348% as a result of the improvement in operating income, reduced financing costs and a contingent tax benefit. We also paid down $1.1 million of term debt in accordance with the various loan provisions. In addition, the ProPhotonix team continues to execute on its long term strategies by successfully launching new products, which we believe will help set the stage for 2017 and beyond."
Full Year 2016 Financial Results
Revenue increased by 13% during 2016 and the gross margin rate improved to 45% resulting from a volume increase and better product mix. Operating expenses totaled $5.9 million (2015: $5.2 million) with sales and marketing expenses up 15% compared to last year at $2.1 million, research and development expenses up $0.2 million, approximately 25%, while general and administrative expenses increased by approximately $0.3 million, 11% over 2015. The Company achieved an operating profit of $1.5 million (2015: $0.8 million) and EBITDA of $1.8 million (2015: $1.2 million). These factors contributed to ProPhotonix's financial improvement and positive net income of $1.3 million (2015: $0.3 million). The balance sheet also continued to improve in 2016. Term debt declined by $1,100,000 to $402,000 as at December 31, 2016.
During 2016, order bookings increased 6% to $16.7 million (2015: $15.7 million), with the book-to-bill ratio at 1.03 (2015: 1.09). Our order book at December 31, 2016 was $5.6 million (2015: $5.6 million).
Customer and Product Development Initiatives:
During the year, the ProPhotonix engineering team completed the development of several products and implemented a number of new technology capabilities. Furthermore, we announced the Company's Cobra ™ Cure FX2 and FX3 products, as well as our new Cobra ™ RGB LED line light. We signed a services agreement with a major medical company in 2016, working to develop a lighting solution for their application. In addition, we entered into an EU funded Fast Track to Innovation program to partner with other participants, including the end customer, in the development of a high power digital laser for a railway industry inspection system. The grant estimate is for up to EUR 360,000 with completion of the entire development project on June 1, 2018.
Building toward the future:
As noted in the Statement to the Shareholders in last year's annual report, the Company's longer term strategy continues to be one of strategic repositioning to include a market(s) directed product portfolio complementing our robust OEM centered business. During 2016, a substantial amount of R&D costs were incurred relating to the development of Cobra Cure products and the multispectral LED products. ProPhotonix has and will continue to make such investments in fulfillment of our strategy. On December 6, 2016, ProPhotonix announced the expansion of its sales team to increase our world-wide sales coverage; with expected further expansion in 2017.
Strategy and Markets
ProPhotonix consists of two business units: an LED systems manufacturing business based in Ireland (Cork), and a laser modules production and laser diode distribution business located in the United Kingdom (Hatfield Broad Oak). Corporate headquarters and the North American sales activities are based in Salem, New Hampshire, USA. The fundamental strategy of the Company is growth in revenue through its existing customers, new customer activity, and new product and market expansion.
We continue to focus on two promising opportunities, concentrating our engineering talents in defined market areas that we believe are poised for fast market expansion. The first of these is the UV LED and laser market for various applications, including printing, curing, bonding, 3D printing, bio-luminescence, medical microscopy and other applications. As noted above, the Company continued its progress in this area with the follow-on COBRA Cure™ product releases. We plan to launch new higher power products while continuously evolving our current product lines to serve this market in 2017 and beyond.
Our remaining focus is on the continuing market requirement for multi-wavelength devices and systems, both laser and LED solutions. Increasingly, customers are seeking multi-wavelength solutions requiring innovative optics, complex electronics, on-board sensing capabilities and sophisticated software control. We see opportunities which include a broad range of applications in printing, microscopy, industrial inspection and sorting, embedded camera and sensor calibration, solar simulation and security markets. As noted, the Company has introduced two new products addressing this market (RGB and Multispec). We intend to enhance and expand this offering as market demand dictates.
ProPhotonix sells its products principally into three markets: industrial (primarily machine vision illumination), medical, and homeland security and defense. The Company foresees growth opportunities in all three markets it serves which are briefly described below:
Industrial (Machine Vision)
Within the industrial market, machine vision is the term used to describe computerized analysis for controlling manufacturing processes, for example automated inspection. In terms of quality and speed, lighting is often a critical component in machine vision and the Company manufactures both LED systems and lasers designed specifically for this market.
The medical and dental market requires many different LED systems and laser modules for unique processes, procedures, and applications. The Company provides a variety of products for medical and dental applications to current customers including, a world leader in stationary imaging equipment, a portable x-ray equipment and dental imaging manufacturer, and a surgical illumination device manufacturer. The Company intends to broaden its product marketing effort in the medical field since it offers significant long-term revenue growth opportunities.
Homeland Security & Defense
LED systems, laser modules and laser diodes are used in a wide variety of applications in the security and defense fields. The Company currently supplies several defense sighting manufacturers in the US and Europe, as well as leading manufacturers of Auto Number Plate Recognition systems. This market offers significant growth opportunities for ProPhotonix over the next several years and the Company is currently marketing its laser and LED capabilities to additional security and optical character recognition systems companies in this market space.
ProPhotonix begins 2017 with a strong order book, and is working with several prospective customers utilizing the Cobra ™ Cure FX series of products for their specific applications. However, there are many complexities and uncertainties which may adversely affect ProPhotonix: economic slowdown, Brexit uncertainty and an ever changing world-wide political landscape. Our management does not dwell on these uncontrollable matters, but remains acutely aware of the necessity for swift response and change if needed. With the backdrop of uncertainty, we remain positive about our business pipeline and confident in our ability to achieve continued positive momentum toward our profitability objectives.
Tim Losik, President and CEO
||Tel: +1 603 893 8778
Stockdale Securities Limited
Tom Griffiths and David Coaten
Tel: +44 (0) 20 7601 6100
|Nominated Adviser and Broker ||
ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com
Click on, or paste the following link into your web browser, to view the associated PDF document.
This information is provided by RNS
The company news service from the London Stock Exchange